Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025

The cost to get a new oncology drug to patients falls by potentially millions of dollars.

Pathos AI, a company employing artificial intelligence for oncology drug development, announced it has secured $237 million in Series E funding. This latest funding round values the company at $3 billion post-money. This valuation represents a significant increase from its previous valuation of $1.6 billion, which was established in May 2025. The company leverages AI to accelerate the discovery and development of cancer treatments.

The substantial increase in Pathos AI's valuation, nearly doubling in less than a year, underscores a robust investor confidence in AI-driven drug discovery. This trend suggests that the market is increasingly favoring companies that can demonstrate tangible progress in using AI to de-risk and expedite the lengthy and expensive process of pharmaceutical development. The success of Pathos AI may encourage further investment in similar ventures, potentially accelerating the adoption of AI across the biotech landscape.

This funding round signals a maturing market for AI in drug development, moving beyond theoretical applications to practical, high-value outcomes. It affects patients by potentially shortening the timeline to novel treatments and reducing the eventual cost of these therapies. Companies in the oncology space, both established pharmaceutical giants and emerging biotechs, will need to evaluate their AI strategies in light of Pathos AI's demonstrated success and investor appetite.